Transcription Factors and MiRNAs Regulate the Mechanism of Drug Resistance in Oesophageal Cancer
The presence of drug resistance can lead to differences in treatment outcomes among patients using the same drug. Therefore, identification of key biological markers associated with drug resistance can help clinicians to quickly select the appropriate drug to prolong the survival time of patients, and it is important for drug development and detailed study of the drug’s mechanism of action. Firstly, we screened different drug resistance and sensitive cell lines in esophageal cancer cell lines to find different drug resistance related genes, and annotated these calculated drug resistance related genes into the transcriptional regulatory network we constructed. The regulatory relationships within this transcriptional regulatory network were all experimentally confirmed and further filtered by real esophageal cancer data to identify drug resistance related modules and key regulators. Thirteen drug resistance-associated modules were identified, each containing 1-6 drug resistance-associated key regulators. Among them, transcription factors SP1, has-miR-21-5p and hsa-miR-1-5p play key regulatory roles in the resistance modules of various drugs, and they regulate drug resistance-associated differentially expressed genes through one-step or multi-step regulatory relationships. Key transcription factors and miRNA in the transcriptional regulatory network that regulate drug resistance-associated genes can be used as potential biomarkers to identify drug resistance to the corresponding drugs in tumor patients.
Jemal A, Bray F, Center MM, et al., 2011, Global Cancer Statistics. CA Cancer J Clin, 61:69–90. DOI: 10.3322/caac.20107
Sjoquist KM, Burmeister BH, Smithers BM, et al., 2011, Survival After Neoadjuvant Chemotherapy or Chemoradiotherapy for Resectable Oesophageal Carcinoma: An Updated Meta-Analysis. Lancet Oncol, 12:681–92. DOI: 10.1016/S1470-2045(11)70142-5
Gibbings DJ, Ciaudo C, Erhardt M, et al., 2009, Multivesicular Bodies Associate with Components of MiRNA Effector Complexes and Modulate MiRNA Activity. Nat Cell Biol, 11:1143–9. DOI: 10.1038/ncb1929
Voorhoeve PM, Sage CL, Schrier M, et al., 2006, A Genetic Screen Implicates MiRNA-372 and MiRNA-373 as Oncogenes in Testicular Germ Cell Tumors. Cell, 124:1169–81. DOI: 10.1016/j.cell.2006.02.037
Huang DW, Sherman BT, Lempicki RA, 2009, Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. Nat Protoc, 4:44–57. DOI: 10.1038/nprot.2008.211
Jiao W, Zhang J, Wei Y, et al., 2019, MiR-139-5p Regulates VEGFR and Downstream Signaling Pathways to Inhibit the Development of Esophageal Cancer. Dig Liver Dis, 51:149–56. DOI: 10.1016/j.dld.2018.07.017
Hummel R, Hussey DJ, Haier J, 2010, MicroRNAs: Predictors and Modifiers of Chemo- and Radiotherapy in Different Tumour Types. Eur J Cancer, 46:298–311. DOI: 10.1016/j.ejca.2009.10.027
Nagesh PKB, Chowdhury P, Hatami E, et al., 2018, MiRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. Cancers (Basel), 10:289. DOI: 10.3390/cancers10090289
Tan W, Liao Y, Qiu Y, et al., 2018, miRNA 146a Promotes Chemotherapy Resistance in Lung Cancer Cells by Targeting DNA Damage Inducible Transcript 3 (CHOP). Cancer Lett, 428:55–68. DOI: 10.1016/j.canlet.2018.04.028
Feng ZY, Xu XH, Cen DZ, et al., 2017, miR-590-3p Promotes Colon Cancer Cell Proliferation Via Wnt/beta-catenin Signaling Pathway by Inhibiting WIF1 and DKK1. Eur Rev Med Pharmacol Sci, 21:4844–52.
Yang W, Soares J, Greninger P, et al., 2013, Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells. Nucleic Acids Res, 41:D955–61. DOI: 10.1093/nar/gks1111
Littlepage LE, Adler AS, Kouros-Mehr H, et al., 2012, The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target During Breast Cancer Progression. Cancer Discov, 2:638–51. DOI: 10.1158/2159-8290.CD-12-0093
Hsu SD, Lin FM, Wu WY, et al., 2011, MiRTarBase: A Database Curates Experimentally Validated MicroRNA-target Interactions. Nucleic Acids Res, 39:D163–9. DOI: 10.1093/nar/gkq1107
Sethupathy P, Corda B, Hatzigeorgiou AG, 2006, TarBase: A Comprehensive Database of Experimentally Supported Animal MicroRNA Targets. RNA, 12:192–7. DOI: 10.1261/rna.2239606
Wingender E, Chen X, Hehl R, et al., 2000, TRANSFAC: An Integrated System for Gene Expression Regulation. Nucleic Acids Res, 28:316–19. DOI: 10.1093/nar/28.1.316
Wang J, Lu M, Qiu C, et al., 2010, TransmiR: A Transcription Factor-microRNA Regulation Database. Nucleic Acids Res, 38:D119–22. DOI: 10.1093/nar/gkp803
Grossman RL, Heath P, Ferretti V, et al., 2016, Toward a Shared Vision for Cancer Genomic Data. N Engl J Med, 375:1109–12. DOI: 10.1056/NEJMp1607591
Tong L, Li C, Wang H, 2019, Trametinib in the Treatment of Multiple Malignancies Harboring MEK1 Mutations. Cancer Treat Rev, 81:101907. DOI: 10.1016/j.ctrv.2019.101907
Asbury RF, Lipsitz S, Graham D, et al., 2000, Treatment of Squamous Cell Esophageal Cancer with Topotecan: An Eastern Cooperative Oncology Group Study (E2293). Am J Clin Oncol, 23:45–46. DOI: 10.1097/00000421-200002000-00013
Kwak AW, Yoon G, Lee MH, et al., 2020, Picropodophyllotoxin, an Epimer of Podophyllotoxin, Causes Apoptosis of Human Esophageal Squamous Cell Carcinoma Cells Through ROS-Mediated JNK/P38 MAPK Pathways. Int J Mol Sci, 21. DOI: 10.3390/ijms21134640
Bi S, Wei Q, Zhao Z, et al., 2019, Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo. Front Pharmacol, 10:864. DOI:10.3389/fphar.2019.00864
Wang Y, Tian J, Han Y, et al., 2016, Gemcitabine Plus Vinorelbine as Second-line Therapy in Patients with Metastatic Esophageal Cancer Previously Treated with Platinum-based Chemotherapy. Oncol Res, 24:129–35. DOI: 10.3727/096504016X14618564639213
Hong J, Maacha S, Belkhiri A, 2018, Transcriptional Upregulation of c-MYC by AXL Confers Epirubicin Resistance in Esophageal Adenocarcinoma. Mol Oncol, 12:2191–208. DOI: 10.1002/1878-0261.12395
Zou J, Li S, Chen Z, et al., 2018, A Novel Oral Camptothecin Analog, Gimatecan, Exhibits Superior Antitumor Efficacy than Irinotecan Toward Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. Cell Death Dis, 9:661. DOI: 10.1038/s41419-018-0700-0
Wang J, Che Y, Yuan Z, et al., 2019, Acetyl-macrocalin B Suppresses Tumor Growth in Esophageal Squamous Cell Carcinoma and Exhibits Synergistic Anti-Cancer Effects with the Chk1/2 Inhibitor AZD7762. Toxicol Appl Pharmacol, 365:71–83. DOI: 10.1016/j.taap.2019.01.005
Hong MH, Heo SG, Lee YG, et al., 2020, Phase 2 Study of Afatinib Among Patients with Recurrent and/or Metastatic Esophageal Squamous Cell Carcinoma. Cancer, 126:4521–31. DOI: 10.1002/cncr.33123
Yang W, Zhao X, Han Y, et al., 2019, Identification of Hub Genes and Therapeutic Drugs in Esophageal Squamous Cell Carcinoma Based on Integrated Bioinformatics Strategy. Cancer Cell Int, 19:142. DOI: 10.1186/s12935-019-0854-6
Tabata M, Tsubaki M, Takeda T, et al., 2020, Dasatinib Reverses Drug Resistance by Downregulating MDR1 and Survivin in Burkitt lymphoma Cells. BMC Complement Med and Ther, 20:84. DOI: 10.1186/s12906-020-2879-8
Wise-Draper TM, Moorthy G, Salkeni MA, et al., 2017, A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Target Oncol, 12:323–32. DOI: 10.1007/s11523-017-0482-9
Chen X, Lu B, Ma Q, et al., 2019, EphA3 Inhibits Migration and Invasion of Esophageal Cancer Cells by Activating the Mesenchymal-Epithelial Transition Process. Int J Oncol. 54:722–32. DOI: 10.3892/ijo.2018.4639
Katoh M, Katoh M, 2018, Integrative Genomic Analyses on HES/HEY Family: Notch-Independent HES1, HES3 Transcription in Undifferentiated ES Cells, and Notch-Dependent HES1, HES5, HEY1, HEY2, HEYL Transcription in Fetal Tissues, Adult Tissues, or Cancer. Int J Oncol,54:722–32. DOI: 10.3892/ijo.2018.4639
Silva P, Neumann M, Schroeder MP, et al., 2017, Acute Myeloid Leukemia in the Elderly Is Characterized by a Distinct Genetic and Epigenetic Landscape. Leukemia, 31:1640–4. DOI: 10.1038/leu.2017.109
Wood LD, Calhoun ES, Silliman N, et al., 2006, Somatic Mutations of GUCY2F, EPHA3, and NTRK3 in Human Cancers. Hum Mutat, 27:1060–1. DOI: 10.1002/humu.9452
Chappell WH, Lehmann BD, Terrian DM, et al., 2012, p53 Expression Controls Prostate Cancer Sensitivity to Chemotherapy and the MDM2 Inhibitor Nutlin-3. Cell Cycle, 11:4579–88. DOI: 10.4161/cc.22852
Eecalilla J, Schokrpur S, Liu C, et al., 2015, CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. Cancer Res, 75:950–62. DOI: 10.1158/0008-5472.CAN-14-0992
Gu J, Zhang J, Chen H, et al., 2016, MicroRNA-130b Promotes Cell Proliferation and Invasion by Inhibiting Peroxisome Proliferator-Activated Receptor-γ in Human Glioma Cells. Int J Mol Med, 37:1587–93. DOI: 10.3892/ijmm.2016.2580
Zhang Y, Chen H Zhou S, et al., 2015, Sp1 and c-Myc Modulate Drug Resistance of Leukemia Stem Cells by Regulating Survivin Expression Through the ERK-MSK MAPK Signaling Pathway. Mol Cancer, 4:56. DOI: 10.1186/s12943-015-0326-0
Kania EE, Carvajal-Moreno J, Hernandez VA, et al., 2020, hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide. Mol Pharm, 297:159–70. DOI: 10.1124/mol.119.118315